Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

VEGF inhibitor

DRUG CLASS:

VEGF inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ivonescimab Sensitive: B - Late Trials ivonescimab Sensitive : B	ivonescimab Sensitive: B - Late Trials ivonescimab Sensitive : B
T-cell-inflamed GEP signature	Renal Cell Carcinoma	T-cell-inflamed GEP signature	Renal Cell Carcinoma	VEGF inhibitor Sensitive: C3 – Early Trials VEGF inhibitor Sensitive : C3	VEGF inhibitor Sensitive: C3 – Early Trials VEGF inhibitor Sensitive : C3
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	VEGF inhibitor Resistant: C3 – Early Trials VEGF inhibitor Resistant : C3	VEGF inhibitor Resistant: C3 – Early Trials VEGF inhibitor Resistant : C3
KDR expression	Cervical Cancer	KDR expression	Cervical Cancer	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	EGFR inhibitor + VEGF inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + VEGF inhibitor Sensitive : C3	EGFR inhibitor + VEGF inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + VEGF inhibitor Sensitive : C3
EGFR negative + ALK negative	Non Small Cell Lung Cancer	EGFR negative + ALK negative	Non Small Cell Lung Cancer	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3
EGFR negative + ALK negative + PD-L1 expression	Non Small Cell Lung Cancer	EGFR negative + ALK negative + PD-L1 expression	Non Small Cell Lung Cancer	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3
KRAS wild-type	Colorectal Cancer	KRAS wild-type	Colorectal Cancer	VEGF inhibitor Sensitive: C3 – Early Trials VEGF inhibitor Sensitive : C3	VEGF inhibitor Sensitive: C3 – Early Trials VEGF inhibitor Sensitive : C3
EGFR L858R + ROS1 fusion	Non Small Cell Lung Cancer	EGFR L858R + ROS1 fusion	Non Small Cell Lung Cancer	recombinant human endostatin Sensitive: C4 – Case Studies recombinant human endostatin Sensitive : C4	recombinant human endostatin Sensitive: C4 – Case Studies recombinant human endostatin Sensitive : C4
ERRFI1 T187A	Ovarian Cancer	ERRFI1 T187A	Ovarian Cancer	rivoceranib + recombinant human endostatin Sensitive: C4 – Case Studies rivoceranib + recombinant human endostatin Sensitive : C4	rivoceranib + recombinant human endostatin Sensitive: C4 – Case Studies rivoceranib + recombinant human endostatin Sensitive : C4